Ftse Mib
33.531,12
0,94%
DAX
18.148,11
0,45%
S&P 500
5.487,03
0,25%
NASDAQ
0,00
0,00%
Bitcoin
66.223,43
1,93%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NYSE Panacea Acquisition Corp (NUVB) Panacea Acquisition Corp (NUVB) Notizie

NUVB

Panacea Acquisition (NUVB)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:NUVB
DataOraFonteTitoloSimboloCompagnia
01/06/202414:10Business WireNuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual MeetingNYSE:NUVBPanacea Acquisition Corp
29/05/202422:05Business WireNuvation Bio to Present at the Jefferies Global Healthcare ConferenceNYSE:NUVBPanacea Acquisition Corp
24/05/202423:22Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNYSE:NUVBPanacea Acquisition Corp
24/05/202422:40Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNYSE:NUVBPanacea Acquisition Corp
14/05/202422:28Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:NUVBPanacea Acquisition Corp
14/05/202422:20Edgar (US Regulatory)Form 8-K - Current reportNYSE:NUVBPanacea Acquisition Corp
14/05/202422:05Business WireNuvation Bio Reports First Quarter 2024 Financial Results and Provides Business UpdateNYSE:NUVBPanacea Acquisition Corp
24/04/202416:01Business WireNuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNYSE:NUVBPanacea Acquisition Corp
10/04/202422:01Business WireNuvation Bio Completes Acquisition of AnHeart TherapeuticsNYSE:NUVBPanacea Acquisition Corp
28/03/202413:00Business WireNuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial OfficerNYSE:NUVBPanacea Acquisition Corp
25/03/202412:00Business WireNuvation Bio to Acquire AnHeart Therapeutics in All-Stock TransactionNYSE:NUVBPanacea Acquisition Corp
14/03/202421:05Business WireNuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid TumorsNYSE:NUVBPanacea Acquisition Corp
04/03/202423:30Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNYSE:NUVBPanacea Acquisition Corp
04/03/202423:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:NUVBPanacea Acquisition Corp
29/02/202423:06Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NYSE:NUVBPanacea Acquisition Corp
29/02/202422:01Business WireNuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNYSE:NUVBPanacea Acquisition Corp
10/01/202422:21Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:NUVBPanacea Acquisition Corp
08/01/202422:58Dow Jones NewsNuvation Bio Gets New Drug Application Clearance From FDA for Solid Tumor TreatmentNYSE:NUVBPanacea Acquisition Corp
08/01/202422:10Business WireNuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of DirectorsNYSE:NUVBPanacea Acquisition Corp
08/01/202422:05Business WireNuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid TumorsNYSE:NUVBPanacea Acquisition Corp
13/11/202322:05Business WireNuvation Bio Announces Departure of Chief Financial OfficerNYSE:NUVBPanacea Acquisition Corp
02/11/202321:10Business WireNuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business UpdateNYSE:NUVBPanacea Acquisition Corp
03/08/202322:10Business WireNuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business UpdateNYSE:NUVBPanacea Acquisition Corp
01/06/202322:05Business WireNuvation Bio Announces Formation of Oncology-Focused Scientific Advisory BoardNYSE:NUVBPanacea Acquisition Corp
17/05/202323:16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:NUVBPanacea Acquisition Corp
16/05/202322:04Edgar (US Regulatory)Current Report Filing (8-k)NYSE:NUVBPanacea Acquisition Corp
04/05/202322:33Edgar (US Regulatory)Quarterly Report (10-q)NYSE:NUVBPanacea Acquisition Corp
04/05/202322:05Business WireNuvation Bio Reports First Quarter 2023 Financial Results and Provides Business UpdateNYSE:NUVBPanacea Acquisition Corp
11/04/202322:27Edgar (US Regulatory)Annual Report to Security Holders (ars)NYSE:NUVBPanacea Acquisition Corp
04/04/202322:10Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NYSE:NUVBPanacea Acquisition Corp
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:NUVB

La tua Cronologia

USOTC
SMDCF
SHL Telemedicine (PK)
POLO
RPLUSDT
Rocket Pool
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network